Tacy Foster

Life sciences companies are spending big on new capital projects. Industry leaders who embrace capital excellence could secure a competitive edge. Life sciences companies are entering a new era of capital intensity. The life sciences industry’s capital expenditures grew 13 percent per year from 2022 to 2024 as biopharma and medtech firms committed tens of billions of dollars to expand production capacity and improve supply chain resilience, particularly in the United States.

October 14, 2024 | Article When it comes to supply chain resilience, have companies taken their eyes off the ball? Supply chain disruptions keep on coming. From missile attacks on commercial shipping in the Red Sea to automotive production delays following floods in Europe, global supply chains continue to experience instability. Meanwhile, trade tensions are choking the movement of semiconductor products, manufacturing equipment, and critical materials.

When it comes to supply chain resilience, have companies taken their eyes off the ball? Supply chain disruptions keep on coming. From missile attacks on commercial shipping in the Red Sea to automotive production delays following floods in Europe, global supply chains continue to experience instability. Meanwhile, trade tensions are choking the movement of semiconductor products, manufacturing equipment, and critical materials.